Antibody data
- Antibody Data
- Antigen structure
- References [0]
- Comments [0]
- Validations
- Flow cytometry [1]
- Other assay [6]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MHCD0817 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- CD8 Monoclonal Antibody (3B5), PE-Texas Red
- Antibody type
- Monoclonal
- Antigen
- Other
- Description
- The R-phycoerythrin (PE)-Texas Red conjugate permits simultaneous multicolor labeling and detection of multiple targets with excitation by a single excitation source-the 488 nm line of the argon-ion laser. This antibody recognizes the alpha chain alone as well as the alpha/beta heterodimer.
- Reactivity
- Human
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- 3B5
- Vial size
- 500 µL
- Storage
- 4° C, store in dark
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Human peripheral blood lymphocytes were stained usingPE-Texas Red® of anti-human CD8 monoclonal antibody (clone 3B5). The negative control profiles represent unstained cells.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 1 PfRH5 vaccination with the ChAd63-MVA platform induces greater activation of total circulating CD8 + and CD4 + T cell populations, while the protein/AS01 B platform elicits a more sustained increase in cTfh-phenotype cells PBMCs from days 0, 7, 14, and 63 were stained ex vivo and analyzed using the gating strategies shown in Figures S1-S3 . (A and B) Increases at day 63 in activated CD38 + Ki67 + cells within total CD8 + and CD4 + T cells (A) or Th1 (CXCR3 + CCR6 - ), Th2 (CXCR3 - CCR6 - ), and Th17 (CXCR3 - CCR6 + ) CD4 + T cell subsets (B) were compared between platforms following subtraction of day 0 CD38 + Ki67 + frequencies in paired samples. (C-E) Frequencies of total cTfh cells defined as CXCR5 + (C) or CXCR5 + PD1 + (D) cells within the CD45RA - CD4 + T cell population were compared between platforms and the frequency of cTfr cells within total cTfh cells (defined as the CD25 + Foxp3 + subset) (E). All of the available samples are plotted (ChAd63-MVA/protein/AS01 B ): day 0, n = 15/54; day 7, n = 15/24; day 14, n = 15/54; day 63, n = 12/20. For intra-trial comparisons (E), only vaccinees with all 4 time points were analyzed: ChAd63-MVA, n = 12, protein/AS01 B , n = 17. Comparisons were performed with Mann-Whitney tests (between trials) or Friedman tests with Dunn's correction for multiple comparisons (within trials comparing day 0 to post-vaccination time points). *p < 0.5, **p < 0.01, and ***p < 0.001. In all of the panels, each point represents a vaccinee.